Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK)

Chemical Compounds

• Polo Like Kinase Inhibitor 100%
• Gemcitabine 70%
• Paclitaxel 56%
• Threonine 52%
• Antiproliferative 47%
• Serine 44%
• Tyrosine 43%
• Molecular Modeling 42%
• Lipid 32%
• Peptide 27%
• Molecule 16%

Medicine & Life Sciences

• LFM A13 93%
• Phosphotransferases 36%
• Breast Neoplasms 30%
• Cell Division 8%
• Inhibitory Concentration 50 8%
• Mitogen-Activated Protein Kinase 14 7%
• Prometaphase 7%
• Bone Marrow Examination 6%
• Spindle Apparatus 5%
• Cell Fusion 5%
• Protein-Serine-Threonine Kinases 5%
• gemcitabine 5%
• Xenopus 5%
• Zebrafish 4%
• Paclitaxel 4%
• Human Activities 4%
• Phosphatidylinositol 3-Kinases 4%
• Glioblastoma 4%
• Embryonic Development 4%
• Protein-Tyrosine Kinases 4%
• Transgenic Mice 4%
• Embryonic Structures 3%
• Adenosine Triphosphate 3%
• Epithelial Cells 3%
• Phosphorylation 3%
• Lipids 3%
• Peptides 3%
• In Vitro Techniques 2%
• Neoplasms 1%